Chen Jie, Liu Xian, Pan Yu-Qin, He Bang-Shun, Ying Hou-Qun, Sun Hui-Ling, Deng Qi-Wen, Lin Kang, Peng Hong-Xin, Wang Shu-Kui
*Department of Life Sciences, Nanjing Normal University; †Central Laboratory, Nanjing First Hospital, Nanjing Medical University; and ‡Medical College, Southeast University, Nanjing, Jiangsu, China.
Int J Gynecol Cancer. 2016 Apr 21. doi: 10.1097/IGC.0000000000000717.
Early diagnosis of ovarian cancer is crucial in clinical practice but is difficult. Accumulating studies have investigated the utility of YKL-40 in early detection of ovarian cancer. The aim of this study was to evaluate the overall accuracy of YKL-40 in diagnosis of ovarian cancer through a meta-analysis of published studies.
A comprehensive search of related literature was performed in PubMed, Web of Science, and China National Knowledge Infrastructure databases. Meta-DiSc 1.4 and STATA 11.0 were selected for data analysis, and Quality Assessment of Diagnostic Accuracy Studies tool version 2 was used to assess the quality of included studies. Data from selected studies were pooled to yield summary sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and summary receiver operating characteristic curve.
A total of 13 studies dating up to May 2015 with 1623 individuals were enrolled in the present study. The pooled characteristics of these studies were as follows: sensitivity 0.71 (95% confidence interval [CI], 0.68-0.75), specificity 0.90 (95% CI, 0.88-0.92), positive likelihood ratio 7.24 (95% CI, 4.22-12.43), negative likelihood ratio 0.34 (95% CI, 0.27-0.42), and diagnostic odds ratio 24.93 (95% CI, 12.61-49.27), respectively. The area under the curve was 0.8471.
The results indicated that YKL-40 could be regarded as an effective biomarker for diagnosis of ovarian cancer.
卵巢癌的早期诊断在临床实践中至关重要，但颇具难度。越来越多的研究探讨了YKL - 40在卵巢癌早期检测中的效用。本研究旨在通过对已发表研究的荟萃分析来评估YKL - 40诊断卵巢癌的总体准确性。
在PubMed、科学网和中国知网数据库中全面检索相关文献。选择Meta - DiSc 1.4和STATA 11.0进行数据分析，并使用诊断准确性研究质量评估工具第2版评估纳入研究的质量。汇总所选研究的数据以得出汇总敏感性、特异性、阳性和阴性似然比、诊断比值比以及汇总接受者操作特征曲线。
本研究共纳入截至2015年5月的13项研究，涉及1623名个体。这些研究的汇总特征如下：敏感性0.71（95%置信区间[CI]，0.68 - 0.75），特异性0.90（95% CI，0.88 - 0.92），阳性似然比7.24（95% CI，4.22 - 12.43），阴性似然比0.34（95% CI，0.27 - 0.42），诊断比值比24.93（95% CI，12.61 - 49.27）。曲线下面积为0.8471。
结果表明，YKL - 40可被视为诊断卵巢癌的有效生物标志物。
